Essential Tremor

Essential Tremor

High-Intensity Focused Ultrasound (HIFU) for Essential Tremor

Official Title:  A Continued Access Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects


Purpose of the Study: The purpose of this study is to assess the safety and effectiveness of MR-guided focused ultrasound (MRgFUS) thalamotomy in patients with Essential Tremor whose medicines are not working well.  The ExAblate transcranial system is the name of the device that will be used to create and send ultrasound waves through the scalp and skull precisely to a small target in the thalamus, which is a structure in the center of the brain.  Essential Tremor is the most common type of tremor that affects people and it tends to run in families and cause tremors when you attempt to use your hands.


Description: Usually, people with ET are treated with medicines to control the tremors.  If the medicines are not effective however, surgery can be used to treat tremors.  Participants are eligible to participate in this study if they have Essential Tremor that is not well-controlled with medications, and it is severe enough to consider surgery to treat the tremors.  We will measure how well the procedure works using questionnaires, neurological assessments, and tremor assessments at each study visit.


Eligibility Criteria: 

Inclusion Criteria

  1. Men and women age 22 years or older.
  2. Subjects who are able and willing to give consent and able to attend all study visits.
  3. A diagnosis of ET as confirmed from clinical history and examination by a neurologist or neurosurgeon specialized in movement disorder.
  4. Tremor refractory to adequate trials of at least two medications, one of which should be a first line therapy of either propranolol or primidone. An adequate medication trial is defined as a therapeutic dose of each medication or the development of side effects as the medication dose is titrated.
  5. Following the 1-month medication stability period, subject must be on stable medication for tremor.
    • The 1-Month stability period visit will be 1-month post consent date
  6. Vim nucleus of thalamus can be target by the ExAblate device. The thalamic region must be apparent on MRI such that targeting can be performed by measurement from a line connecting the anterior and posterior commissures of the brain.
  7. Able to communicate sensations during the ExAblate TcMRgFUS treatment.
  8. Postural or intention tremor severity score of greater than or equal to 2 in the dominant hand/arm as measured by the CRST rating scale while stable on medication.
  9. May have bilateral appendicular tremor.
  10. Significant disability due to essential tremor despite medical treatment (CRST score of 2 or above in any one of the items 16-23 from the Disability subsection of the CRST: [speaking, feeding other than liquids, bringing liquids to mouth, hygiene, dressing, writing, working, and social activities]).
  11. Inclusion and exclusion criteria have been agreed upon by two members of the medical team.
  12. Subjects on stable antidepressant medications for at least 3 months may be enrolled into this study (i.e., no change in medication drug or dosage for 3 months).


Exclusion Criteria

  1. Subjects with unstable cardiac status including:
    • Unstable angina pectoris on medication.
    • Subjects with documented myocardial infarction within six months of protocol entry.
    • Significant congestive heart failure defined with ejection fraction < 40.
    • Subjects with unstable ventricular arrhythmias.
    • Subjects with atrial arrhythmias that are not rate-controlled.
  2. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the following occurring within a 12 month period:
    • Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household).
    • Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use).
    • Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct).
    • Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights).
  3. Severe hypertension (diastolic BP > 100 on medication).
  4. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  5. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease.
  6. Patient with severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis.
  7. History of abnormal bleeding and/or coagulopathy.
  8. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure.
  9. Active or suspected acute or chronic uncontrolled infection.
  10. History of immunocompromise including those who are HIV positive.
  11. History of intracranial hemorrhage.
  12. Cerebrovascular disease (multiple CVA or CVA within 6 months).
  13. Subjects with uncontrolled symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, papilledema).
  14. Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (can be up to 4 hrs of total table time).
  15. Are participating or have participated in another clinical trial in the last 30 days.
  16. Significant claustrophobia that cannot be managed with mild medication.
  17. Subjects unable to communicate with the investigator and staff.
  18. Presence of any other neurodegenerative disease such as Parkinson-plus syndromes suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer’s disease.
  19. Anyone suspected to have the diagnosis of idiopathic Parkinson’s disease.
  20. Anyone with the presence of parkinsonian features including bradykinesia, rigidity, or postural instability will be excluded. Subjects who exhibit only mild resting tremor but no other symptoms or signs of PD may be included.
  21. Presence of significant cognitive impairment as determined with a score ≤ 24 on the Mini Mental Status Examination (MMSE).
  22. Subjects with life-threatening systemic disease that include and not limited to the following will be excluded from the study participation: HIV, Liver Failure, blood dyscrasias, etc.
  23. Subjects with a history of seizures within the past year.
  24. Subjects with presence or history of psychosis will be excluded. Subjects with significant or active mood disorders including depression will be excluded. For purpose of this study, we consider a significant mood disorder to include any subject who:
    • Scores ≥ 20 on the PHQ-9 questionnaire.
    • Is currently under the care of a psychiatrist.
    • Is currently participating in cognitive-behavioral therapy.
    • Has been hospitalized for the treatment of a psychiatric illness within 12 months.
    • Has ever received transcranial magnetic stimulation.
    • Has ever received electroconvulsive therapy.
  25. Subjects with risk factors for intraoperative or postoperative bleeding: platelet count less than 100,000 per cubic millimeter, INR coagulation studies exceeding local institution laboratory standards, or a documented coagulopathy.
  26. Subjects with brain tumors.
  27. Any illness that in the investigator's opinion preclude participation in this study.
  28. Pregnancy or lactation.
  29. Legal incapacity or limited legal capacity.
  30. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia.
  31. Subjects who have been administered botulinum toxins into the arm, neck, or face for 5 months prior to Baseline.
  32. Subjects who have an Overall Skull Density Ratio of 0.45 (±0.05) or less as calculated from the screening CT.


Study Status: Enrolling  


Principal Investigator:  Dr. Ali Rezai


Contact: Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Funding/Study Sponsor: InSightec

Obsessive Compulsive Disorder

Obsessive Compulsive Disorder

Deep Brain Stimulation (DBS) Therapy for Obsessive Compulsive Disorder (OCD)

Purpose of Study: This study plans to enroll up to 10 subjects who have been diagnosed with obsessive compulsive disorder (OCD). Once consented, the participant will undergo a Positron Emission Tomography/ Computerized Tomography (PET/CT) scan, Electroencephalography (EEG) with event-related potentials (ERP), and cognitive assessments prior to the DBS surgery. After surgery, the participant will repeat the PET/CT scan, EEG/ERP, and cognitive assessments every six months for two years. A total of five study visits is require for the study. Additional visits may be required if the PET/CT scan, EEG/ERP, and cognitive assessments cannot be scheduled or completed on the same day.


Eligibility Criteria: Patients who are candidates and are scheduled for deep brain stimulation (DBS) surgery for treatment-resistant OCD under FDA approval of HDE #H050003 will be approached and asked to participate in this research study. There is no additional eligibility criterion.


Status of Study: Open to Enrollment


Principal Investigator: Ali Rezai, MD


Contact: Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Sponsor: Ali Rezai, MD

Reclaim Deep Brain Stimulation (DBS) Therapy for Obsessive Compulsive Disorder

Purpose of Study: The Food and Drug Administration (FDA) gave approval of the Humanitarian Device Exemption (HDE) a Humanitarian use device for Medtronic Reclaim Therapy to Medtronic, Inc. (HDE# H050003). Medtronic Reclaim Deep Brain Stimulation (DBS) Therapy for Obsessive Compulsive Disorder (OCD) delivers electrical stimulation to areas in the brain to help control symptoms of treatment resistant OCD. The Medtronic Reclaim DBS Therapy is indicated for bilateral stimulation of a specific region of the brain (anterior limb of the internal capsule), in conjunction with OCD medications for treatment of chronic, severe, treatment resistant OCD in adult patients who have failed at least three selective serotonin reuptake inhibitor medications. DBS is used as an alternative to anterior capsulotomy (different type of surgery) that is indicated for this condition.


Principal Investigator: Ali Rezai, MD


Contact: Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu

Other Conditions

Other Conditions

Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache

Purpose of Study: The primary objective of the study is to demonstrate the safety and efficacy of SPG stimulation with the ATI Neurostimulation System when used to treat acute cluster attacks in chronic cluster headache patients.


Description of Study: Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.


Eligibility Criteria: Men and women age 22 or older who have been diagnosed with chronic cluster headache according to the 2013 ICHD, 3rd edition (beta version), criterion 3.1.2 and report a minimum of four cluster attacks per week on the side of their dominant headache laterality. Subjects who report more than eight attacks per day or attack duration of less than 30 minutes (untreated or unsuccessfully treated) must have been tested to rule out other forms of trigeminal autonomic cephalalgias.


Also:

  • Both subject and physician judge previously or currently used preventive and/or acute cluster headache treatment to be inadequate.
  • Subject is able to distinguish cluster attacks from other headaches (e.g., migraine, tension-type headaches).
  • Subject agrees to not use therapy involving TENS or magnetic field treatment while the Neurostimulator is implanted.
  • Subject agrees to not participate in supplemental or alternative therapy, including acupuncture and spinal manipulation, from Study Enrollment through the end of the Experimental Period of the study.
  • Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency or dose) – except to manage tolerability – from Study Enrollment through the Experimental Period of the study.
  • Subject agrees not to use any acute medications, including oxygen therapy, for their treatable cluster attacks during the Experimental Period until after they have used SPG stimulation therapy for at least 15 minutes.
  • Subject has had a dental examination and cleaning in the past six months.
  • Subject has the ability to read and comprehend, and to reliably record information as required by the Protocol.
  • Subject is able to provide written informed consent prior to participation in the study.

Status of Study: Recruiting


Principal Investigator: Bradley Otto, MD


Contacts:
Bradley Otto, MD
Phone: 855-255-0550
Email: Brad.otto@osumc.edu


Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Sponsor: Autonomic Technologies, Inc.

Concurrent Deep Brain Stimulation (DBS) Local Field Potential Analysis And Stimulation In A Closed-Loop Neuromodulation Device

Purpose of Study: The protocol plans to monitor Local Field Potentials (LFP) signals following implantation of STN DBS using the Activa PC+S.


Description of Study: Recordings will be acquired within 48 hours following IPG implantation and/or prior to initiation of stimulation therapy 30 days after insertion. This will address questions of the immediate passive effect observed clinically following DBS implantation and also the fluctuation of LFP activity over a 30-day period prior to turning on the DBS system. Following this period, LFP activity will be recorded during standard adjustments of differing stimulation parameters with correlation to changes in disease symptoms and clinical presentation as reflected in disease rating scales. This will allow for a more objective assessments approach of LFP with regards to the standard clinical guided DBS programming evaluations.


Additionally, specialized motor and cognitive tasks will be used to allow for the study of LFP response from implantable DBS electrodes in the STN. This will allow the generation of objective measurements for the degree of manifested deficits, and consequently, will allow us to grade the effect of deep brain stimulation on these measures. Second, by measuring the LFP during variable parts of the motor and cognitive tasks and with different stimulation parameters, we will be able to correlate clinical improvements with neurophysiological changes, thereby allowing us to identify biomarkers of stimulation and treatment effectiveness that depend only on electrophysiologic brain properties.


Eligibility Criteria: Men and women age 22 to 90 who are candidates for DBS surgery, willing to comply with all follow-up evaluations at the specified study time points, able to provide informed consent prior to enrollment in the study, and fluent in English.


Status of Study: Open to enrollment


Principal Investigator: Ali Rezai, MD


Contact: Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Sponsor: Ali Rezai, MD

Deep Brain Stimulation for the Treatment of Obesity

Purpose of Study: The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS) as a treatment option for obesity.


Description of Study: Patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.


Eligibility Criteria: Men and women age 22 to 60 who are at least 24 months post Roux-en-Y gastric bypass surgery without evidence of a sustained improvement in BMI after gastric bypass surgery for at least six months; willing to comply with all follow-up evaluations at the specified times; able to provide informed consent, and fluent in English.


Status of Study: Recruiting


Principal Investigator: Ali Rezai, MD


Contacts:
Rebecca Dettorre, CCRC
Phone: 614-293-8549
Email: becky.dettorre@osumc.edu

Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Sponsor: Ali Rezai, MD

Activa Dystonia Deep Brain Stimulation (DBS) Therapy

Purpose of Study: This protocol is for a Humanitarian Device Exemption (HDE). The Food and Drug Administration (FDA) gave approval of the HDE of a Humanitarian Use Device (HUD) for Medronic Activa® Dystonia Therapy on April 13, 2003, to Medtronic, Inc. (HDE Number: H020007) and it was approved at Ohio State University on May 10, 2010. Medtronic Activa® Deep Brain Stimulation Dystonia Therapy delivers electrical stimulation to internal globus pallidus (GPi) or the subthalamic nucleus (STN) to aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia and cervical dystonia (torticollis) in patients seven years of age or above who have completed at least one year of other treatment before being considered a surgical candidate.


Description of Study: This is not a research study; it is an FDA requirement for humanitarian use of the deep brain stimulation device in treating a rare disease, dystonia.


Eligibility Criteria: Patients seven years of age or older with chronic, intractable (drug refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia and cervical dystonia (torticollis) who have completed at least one year of other treatment.


Principal Investigator: Ali Rezai, MD


Contact: Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu

High-Intensity Focused Ultrasound (HIFU) for Parkinson's Disease

Official Title: A Phase I Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson’s Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System


Purpose of the Study: We are doing this study to show that the ExAblate procedure is safe and works like we think it will.  There is some evidence in the medical literature that shows that by ablating a particular cluster of cells in your brain, your motor symptoms may improve.  This technology is one method of performing the ablation without cutting or penetrating through your skin or skull bone.  For this study we are inviting subjects whose medicines are not working well in controlling their motor symptoms to participate.


Description: Usually, people with Parkinson’s Disease are treated with medicines to control the tremors.  If the medicines are not effective however, surgery can be used to treat tremors.  Participants are eligible to participate in this study if they have Parkinson’s Disease that is not well-controlled with medications, and it is severe enough to consider surgery to treat.  We will measure how well the procedure works using questionnaires, neurological assessments, and Parkinson’s Disease Rating Scale at each study visit.


Eligibility Criteria:

Inclusion Criteria

  1. Men and women, age 30 years and older.
  2. Subjects who are able and willing to give informed consent and able to attend all study visits through 24 months.
  3. Subjects with a diagnosis of idiopathic PD by UK Brain Bank Criteria as confirmed by a movement disorder neurologist at the site.
  4. Levodopa responsive as defined by at least a 30% reduction in MDS-UPDRS motor subscale in the ON vs OFF medication state.
  5. MDS-UPDRS score of ≥ 30 in the meds OFF condition.
  6. Disabling motor complications of PD on optimum medical treatment characterized dyskinesia or motor fluctuations (MDS-UPDRS item 4.2 score of 2 or 3 in the meds ON condition).
  7. Predominant disability from one side of the body.
  8. Subjects should be on a stable dose of all PD medications for 30 days prior to study entry.
  9. Subject is able to communicate sensations during the ExAblate Neuro procedure.


Exclusion Criteria

  1. Hoehn and Yahr stage in the ON medication state of 3 or greater.
  2. Presence of other central neurodegenerative disease suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, corticobasal syndrome, dementia with Lewy bodies, and Alzheimer’s disease.
  3. Any suspicion that Parkinsonian symptoms are a side effect from neuroleptic medications.
  4. Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia.
  5. Presence of significant cognitive impairment defined as score ≤ 21 on the Montreal Cognitive Assessment (MoCA) or Mattis Dementia Rating Scale of 120 or lower.
  6. Unstable psychiatric disease, defined as active uncontrolled depressive symptoms, psychosis, delusions, hallucinations, or suicidal ideation. Subjects with stable, chronic anxiety or depressive disorders may be included provided their medications have been stable for at least 60 days prior to study entry and if deemed appropriately managed by the site neuropsychologist.
  7. Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist. Significant depression is being defined quantitatively as a score of greater than 14 on the Beck Depression Inventory.
  8. Legal incapacity or limited legal capacity as determined by the neuropsychologist.
  9. Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the following occurring within the preceding 12 month period:
    • Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household).
    • Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use).
    • Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct).
    • Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights).
  10. Subjects with unstable cardiac status including:
    • Unstable angina pectoris on medication.
    • Subjects with documented myocardial infarction within six months of protocol entry.
    • Significant congestive heart failure defined with ejection fraction < 40.
    • Subjects with unstable ventricular arrhythmias.
    • Subjects with atrial arrhythmias that are not rate-controlled.
  11. Severe hypertension (diastolic BP > 100 on medication).
  12. Current medical condition resulting in abnormal bleeding and/or coagulopathy.
  13. Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure.
  14. Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: platelet count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or INR coagulation studies exceeding the institution’s laboratory standard.
  15. Patient with severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis.
  16. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  17. Significant claustrophobia that cannot be managed with mild medication.
  18. Subject who weigh more than the upper weight limit of the MR scanner table and who cannot fit into the MR scanner.
  19. Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.
  20. History of intracranial hemorrhage.
  21. History of multiple strokes, or a stroke within past 6 months.
  22. Subjects with a history of seizures within the past year.
  23. Subjects with brain tumors.
  24. Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment.
  25. Are participating or have participated in another clinical trial in the last 30 days.
  26. Any illness that in the investigator's opinion preclude participation in this study.
  27. Subjects unable to communicate with the investigator and staff.
  28. Pregnancy or lactation.
  29. All patients with severe premorbid risks [MDS-UPDRS Part II subsection activities of daily living scores of a three or four in question 2.1 (speech), question 2.2 (salivation), or question 2.3 (swallowing)] will be excluded.


Study Status: Recruiting


Principal Investigator: Dr. Vibhor Krishna


Contact: Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Funding/Study Sponsor: InSightec

RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

Purpose of Study: To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Directions for Use. Also, to evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice.


Description of Study: The study is a prospective, multicenter, global registry of Boston Scientific neurostimulation systems for pain. The study treatment will consist of neurostimulation trial therapy with any commercially approved Boston Scientific Corporation neurostimulator for pain. Positive trials, subjects with a successful trial outcome, may progress to permanent implant of a neurostimulation system. Individualization of neurostimulation therapy for pain will be determined according to investigator discretion and site routine care, and in accordance with inclusion and exclusion criteria.


Eligibility Criteria: Men and women age 18 and older who are scheduled to be trialed, on-label, with a commercially approved Boston Scientific neurostimulation system for pain, per local directions for use, and have signed a valid, IRB/EC-approved informed consent form.


Status of Study: Recruiting


Principal Investigator: Milind Deogaonkar, MBBS


Contact:
Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Sponsor: Boston Scientific Corporation

More +

Reanimation in Tetraplegia

Purpose of Study: The purpose of this clinical study is to allow the investigation of the Neural Bridging System for participants with tetraplegia to assess if the investigational device can reanimate a paralyzed limb under voluntary control by the participant's thoughts.


Description of Study: This study plans to enroll participants who have been diagnosed with C4- C6 ASIA A spinal cord injuries (motor and sensory complete neurologic injuries), who are more than one year post injury, and who are neurologically stable.


Eligibility Criteria: Men and women age 21 to 89 who are tetraplegic (C4- C6 ASIA A), 12 months post injury and neurologically stable, willing to comply with all follow-up evaluations at the specified times, able to provide informed consent prior to enrollment in the study, fluent in English, and have a caregiver willing to participate in the study who will provide care for the surgical site.


Status of Study: Recruiting


Principal Investigator: Ali Rezai, MD


Contact: Amelia Hargrove
Phone: 614-366-6639
Email: amelia.hargrove@osumc.edu


Sponsor: Ali Rezai, MD

Share this Page